Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total value of $83,792.04. Following the completion of the transaction, the director now owns 7,167,110 shares in the company, valued at $52,463,245.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 25th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.51, for a total value of $108,860.97.
• On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.45, for a total value of $96,727.15.
• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.17, for a total value of $104,968.99.
• On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.66, for a total value of $87,684.02.

Recursion Pharmaceuticals Price Performance

RXRX traded up $0.45 during trading on Thursday, reaching $7.68. 8,418,305 shares of the stock were exchanged, compared to its average volume of 6,204,676. The business’s 50 day moving average price is $8.74 and its two-hundred day moving average price is $9.81. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -4.86 and a beta of 0.83. Recursion Pharmaceuticals, Inc. has a 1 year low of $4.97 and a 1 year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. Recursion Pharmaceuticals’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.34) earnings per share. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Needham & Company LLC restated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the company. National Bank of Canada FI raised its holdings in shares of Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after acquiring an additional 1,500 shares during the last quarter. Wedmont Private Capital raised its holdings in shares of Recursion Pharmaceuticals by 11.8% in the first quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock worth $172,000 after acquiring an additional 2,000 shares during the last quarter. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals in the first quarter worth $26,000. Arizona State Retirement System raised its holdings in shares of Recursion Pharmaceuticals by 8.5% in the fourth quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock worth $394,000 after acquiring an additional 3,125 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Recursion Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 16,359 shares of the company’s stock worth $161,000 after acquiring an additional 4,148 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.